Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 11/20 | 1.00 |
| ▸ | CARM1 | Q86X55 | 10/20 | 1.00 |
| ▸ | CCR3 | P51677 | 2/20 | 0.67 |
| ▸ | PRMT8 | Q9NR22 | 2/20 | 0.65 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.65 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.65 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.63 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.63 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8966093 | 0.91 | PRMT6 (1.00) | PRMT6CARM1CCR3PRMT8PRMT3 | |
| SCHEMBL8966097 | 0.91 | PRMT6 (1.00) | PRMT6CARM1CCR3PRMT8PRMT3 | |
| SCHEMBL13745477 | 0.91 | PRMT6 (0.83) | PRMT6CARM1CCR3PRMT8PRMT3 | |
| SCHEMBL20467905 | 0.88 | PRMT6 (0.79) | PRMT6CARM1CCR3PRMT8PRMT3 | |
| SCHEMBL22844319 | 0.85 | CARM1 (1.00) | PRMT6CARM1PRMT8SIGMAR1TMEM97 | |
| SCHEMBL19880384 | 0.84 | PRMT6 (0.72) | PRMT6CARM1CCR3PRMT8PRMT3 | |
| SCHEMBL22966103 | 0.84 | PRMT6 (0.72) | PRMT6CARM1CCR3PRMT8PRMT3 | |
| SCHEMBL27016353 | 0.84 | PRMT6 (0.82) | PRMT6CARM1CCR3PRMT8PRMT3 | |
| SCHEMBL18325109 | 0.84 | PRMT6 (0.72) | PRMT6CARM1CCR3PRMT8PRMT3 | |
| SCHEMBL29448595 | 0.83 | PRMT6 (0.71) | PRMT6CARM1CCR3PRMT8PRMT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160369247-A1 | SUBSTRATE-MIMETIC AKT INHIBITOR | UNIVERSITY OF SOUTH FLORIDA (US) | 2016-12-22 | — | — | US | disclosed |
| US-9453049-B2 | Substrate-mimetic Akt inhibitor | UNIVERSITY OF SOUTH FLORIDA (US) | 2016-09-27 | — | — | US | disclosed |
| US-9453049-B2 | Substrate-mimetic Akt inhibitor | UNIVERSITY OF SOUTH FLORIDA (US) | 2016-09-27 | — | — | US | disclosed |
| US-20150004698-A1 | SUBSTRATE-MIMETIC AKT INHIBITOR | YALE UNIVERSITY (US) | 2015-01-01 | — | — | US | disclosed |
| US-20150004698-A1 | SUBSTRATE-MIMETIC AKT INHIBITOR | YALE UNIVERSITY (US) | 2015-01-01 | — | — | US | disclosed |
| US-20130310373-A1 | PYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-11-21 | — | — | US | disclosed |
| US-8524727-B2 | Pyrimidine compound | ASTELLAS PHARMA INC. (JP) | 2013-09-03 | — | — | US | disclosed |
| US-8524727-B2 | Pyrimidine compound | ASTELLAS PHARMA INC. (JP) | 2013-09-03 | — | — | US | disclosed |
| EP-2415765-A1 | PYRIMIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20110053912-A1 | PYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-03-03 | — | — | US | disclosed |
| US-20110053912-A1 | PYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-03-03 | — | — | US | disclosed |
| WO-2010113834-A1 | PYRIMIDINE COMPOUND | アステラス製薬株式会社 (JP) | 2010-10-07 | — | — | WO | disclosed |
| US-20100009397-A1 | SUBSTRATE-MIMETIC AKT INHIBITOR | UNIVERSITY OF SOUTH FLORIDA (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009397-A1 | SUBSTRATE-MIMETIC AKT INHIBITOR | UNIVERSITY OF SOUTH FLORIDA (US) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053912-A1 | PYRIMIDINE COMPOUND | CNR2, CNR1, P2RY2 | PRMT6 3352/4885CARM1 3460/4885CCR3 635/4885 |
| US-20130310373-A1 | PYRIMIDINE COMPOUND | CNR2, CNR1, P2RY2 | PRMT6 3611/4885CARM1 3631/4885CCR3 480/4885 |
| US-20160369247-A1 | SUBSTRATE-MIMETIC AKT INHIBITOR | GSKIP, AKT3, GSK3B | PRMT6 540/4885CARM1 2124/4885CCR3 3186/4885 |
| US-20150004698-A1 | SUBSTRATE-MIMETIC AKT INHIBITOR | GSKIP, AKT3, GSK3B | PRMT6 540/4885CARM1 2124/4885CCR3 3186/4885 |
| US-20100009397-A1 | SUBSTRATE-MIMETIC AKT INHIBITOR | GSKIP, AKT3, GSK3B | PRMT6 540/4885CARM1 2124/4885CCR3 3186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.